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Abstract
The effects of tumor necrosis factor (TNF) and interleukin-1 (IL-1) on infection with murine 
cytomegalovirus (MCMV) were investigated in vitro and in vivo. The addition of each o f  these 
cytokines (at 1 ng/ml) to tissue culture monolayers 24 hr prior to MCMV challenge produced 
a reproducible decrease in vital titer (from 1 x 10s pfu to approximately 4 x 106 pfu for both 
cytokines). There was no further increase in this effect when a 10 or 100 ng/ml o f each o f  these 
cytokines was employed. Despite these in vitro effects, the pretreatment o f  suckling, weanling, 
or adult mice with 80 or 400 ng o f TNF or IL-1 alone, or 80 ng o f each cytokine together, had 
no effect on the survival of mice following MCMV. Similarly, neither o f these cytokines 
adversely influenced the protective effects of hyperimmune anti-MCMV antiserum; that is, they 
did not attenuate the protection conferred by the antiserum nor affect the protective effects o f  
subtherapeutic doses of the antiserum. We conclude that despite promising antiviral effects 
against MCMV in vitro, these agents do not result in a useful therapeutic effect in vivo. 
Moreover, despite the ability o f IL-1 to induce ACTH and corticosterone in mice, IL-1 
treatment did not increase the mortality to CMV.
Interleukin-1 (IL-1) and tumor necrosis 
factor alpha (TNF) are cytokines produced 
by mononuclear phagocytes in response to 
inflammatory stimuli which mediate the acute 
phase response [1,2]. A deleterious role for 
these cytokines has been postulated to occur 
in the pathogenesis of the protean clinical 
manifestations of gram negative sepsis. How­
ever, we have previously demonstrated that 
the administration of a low dose of human 
recombinant IL-1 is capable o f protecting 
neutropenic mice with a lethal Pseudomonas  
aeruginosa  or Candida albicans infection 
[3, 4]. In addition, increased nonspecific resis­
tance to Klebsiella pneumoniae  infection has 
been induced with recombinant IL-1 [5,6] 
and recombinant TNF [6, 7].
These studies raise the possibility that cy­
tokines might have potential utility in the 
treatment o f life-threatening infection, partic­
ularly infection occurring in immunocompro­
mised individuals. A particularly challenging 
form of infection in this clinical context is 
that caused by cytomegalovirus (CMV). Re­
cently, several groups [8 -14] have reported 
that TNF has significant antiviral effects, 
both by itself and in synergistic combination 
with gamma interferon, when assayed in 
vitro. In these studies, one o f the viruses most 
intensively studied was herpes simplex virus, 
a herpes group virus closely related to CMV. 
In addition, IL-1 and T N F  have been shown 
to induce beta interferon in fibroblasts in 
vitro [15]. Because of these observations, and
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because current therapy o f  life-threatening 
CMV syndromes (even with the antiviral drug 
gancyclovir) remains difficult [16], we em­
barked on a series o f studies to evaluate the 
effects o f  IL-1 and T N F on the course o f CMV 
infection. Utilizing the murine CMV system we 
were able to demonstrate a significant anti viral 
effect in v itro ,  but not in vivo. The course of  
murine CMV (M CM V) in mice of varying ages 
appears to be unaffected by the exogenous 
administration of recombinant IL-1 or TNF.
Materials and methods
A n im a ls
Female BALB/c mice obtained from Cumber­
land View Farms (Clinton, TN) were used in 
all in vivo  experiments. One week old mice were 
used in the experiments in which suckling 
animals were employed, three week old mice in 
the experiments in which weanling mice were 
employed, and six week old mice in the exper­
iments in which adult mice were employed. 
Infected mice were kept in bonneted cages to 
prevent cross infection, with no more than six 
animals per cage. They were maintained on 
Purina Laboratory Chow and water a d  lib.
Virus
The Smith strain o f  MCMV, originally ob­
tained as a 10% (wt/vol) homogenate of in­
fected salivary gland tissue from Dr. John D. 
Shanley (Veterans Administration Medical 
Center, University o f Connecticut, Newington, 
CT), was used in these experiments. The virus 
is maintained in this laboratory by serial 
passage in CD-I Swiss Webster mice (Charles 
River Breeding Laboratories, Inc., Wilming­
ton, M A). Three week old CD-I mice were 
inoculated intraperitoneally with 104 plaque 
forming units (pfu) o f  MCMV. Twenty-one 
days after infection, the salivary glands were 
harvested and homogenized in Dulbecco’s 
Medium containing 10% fetal calf serum and 
10% dimethyl sulfoxide. The virus stock was
a 10% (wt/vol) homogenate o f infected sali­
vary gland with a titer of 2 x 10s pfu/ml. 
Uninfected salivary gland homogenates 
(NSG) were prepared in a similar fashion from 
weanling mice inoculated with saline. Both 
stocks were stored at — 70°C until used [17].
Virologic techniques
Quantitative assays for infectious virus were 
performed on tissue homogenates (10% wt/ 
vol) prepared in Dulbecco’s medium contain­
ing 10% fetal calf serum. These were then 
assayed in secondary mouse embryo fibro­
blasts prepared from 12-15 day CD-I Swiss 
Webster embryos under an overlay with 1% 
methylcellulose according to previously de­
scribed methods [10].
Experim enta l design
In the in vivo experiments, adult or weanling 
mice were administered one of the following 
regimens intraperitoneally (ip ): 400 or 80 ng of 
recombinant IL-1 beta (obtained from Cistron 
Biotechnology, Inc., Pinebrook, NY or Glaxo 
Institute o f Molecular Biology, Geneva, 
Switerland), 80 ng o f human recombinant 
TNF alpha (Biogen, Inc., Cambridge, MA), or 
a combination of 80 ng o f both cytokines. In 
one series of experiments, the cytokine admin­
istration was followed two hours later by the 
ip administration of 0.2 ml of a variety of 
dilutions of a hyperimmune anti-MCMV anti­
serum prepared as previously described [12]. 
Twenty-four hours later, mice were challenged 
ip with a variety of doses o f MCMV or with 
an equal volume o f NSG. Mice were then 
monitored on a daily basis for mortality. In 
experiments in which suckling mice were em­
ployed, the same experimental design was 
employed, except that lower doses of the 
cytokines were employed: 40 ng of either IL-1, 
TNF, or both.
In the in vitro  experiments, secondary mouse 
embryo fibroblasts (MEF) were prepared from 
embryos of 12-15 day CD-I Swiss Webster 
mice as described above. Cells were maintained
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in Dulbecco’s minimum essential medium 
containing 10% fetal calf serum, 200 U  of 
penicillin per ml, and 200 meg o f strepto­
mycin per ml. Secondary MEF monolayers 
were plated in six or twelve well tissue culture 
plates (Falcon Plastics, Oxnard, CA) with 
Dulbecco’s medium. Cell layers were treated 
with purified recombinant human gamma in­
terferon (Biogen, Inc., Cambridge, MA), IL-1 
beta, TNF alpha, or combinations of these, 
at concentrations o f 1, 10, or 100 ng/ml in 
Dulbecco’s medium. After 24 hr incubation 
at 37°C and 5% C 0 2, supernatants were 
removed and the cell layer washed twice with 
fresh medium. MCMV was then added with 
an MOI =  1. Control wells did not receive 
any virus or received only virus. Cells were 
incubated for 90 min at 37°C in 5% C 0 2 with 
rocking of the plate every 15 minutes to 
ensure the spread of virus and maximize ad­
sorption. Two ml o f media were then added 
to each well, and plates were incubated for 5 
days under the same conditions. On day 5, 
supernatants were collected and frozen at 
-70°C . These were subsequently thawed and 
quantitatively assayed for the amount of 
virus present as described above.
Results
The addition o f TNF, IL-1, and gamma in­
terferon to tissue culture monolayers 24 hr 
prior to challenge with MCMV produced a 
reproducible decrease in viral titer (from 
9.1 x 107pfu/ml to approximately 2.5 x 106 
pfu/ml for all three cytokines). There was no 
significant difference in the magnitude of the 
effect, whether 1, 10, or 100 ng/ml o f each of 
these cytokines was employed (Table 1).
The pretreatment o f suckling, weanling, or 
adult mice with IL-1 or TNF either alone or 
together had no effect on the survival of mice 
following challenge with MCMV. Similarly, 
there were no discernible adverse effects of 
these cytokines when they were administered 
to animals challenged with noninfected sali-
Tabie 1. Effects of interleukin-1 (IL-1) tum or necrosis factor 
(TNF), and interferon (IFN) on murine cytomegalovirus in 
vitro*
Treatment Dose Viral titer (pfu)
None _ 9.1 x IO7
TNF 1 ng 4.2 x 106
TNF 10 ng 2.1 x  106
TNF 100 ng 2.2 x 106
IL-1 1 ng 2.5 x  106
IL-1 10 ng 2.9 x 106
IL-1 100 ng 2.6 x 106
IFN 1 ng 2.8 x  106
IFN 10 ng 1.7 x 106
IFN 100 ng 1.1 x 106
* Results are the mean values obtained in three separate 
experiments in which each determination was carried out in 
duplicate.
vary gland homogenate (NSG ). In addition 
to the lack of effect o f these cytokines on 
animal survival (Table 2), there was no effect 
on the time of death in animals (data not 
shown).
Pretreatment o f animals with hyperimmune 
anti-MCMV antiserum provided full protec­
tion against lethal challenge when a 1 : 4 dilu­
tion of the antiserum was employed, but no 
protection when a 1 : 16 dilution was admin­
istered. The addition o f 80 ng o f IL-1 to these 
therapies had no discernible effect in that 
it did not detract from the efficacy o f  the 
1 :4 dilution o f antiserum and did not 
improve the results obtained with the 1 : 16 
dilution (Table 3).
Discussion
There are now several reports suggesting that 
tumor necrosis factor and other cytokines will 
selectively kill virus-infected cells in tissue 
culture systems [8-14]. Am ong the viruses 
shown to be susceptible to this effect are 
herpes simplex virus, vesicular stomatitis 
virus, adenovirus, and encephalomyocarditis 
virus. Because of the need for more effective 
treatment regimens in the management of 
cytomegalovirus infection, particularly in
2 3 0
Table 2. Effects o f pretreatm ent with interleukin-1, tumor necrosis factor, on both the survival o f  mice challenged intraperitoneally 
with m urine cytomegalovirus.*
Age o f mouse** Dose o f virus (pfu) Pretreatment Survival
#  survival/ #  challenged
A. Suckling I x 104 diluent 2/21
1 x 10“ 40 ng IL-I 1/21
1 x 10“ 40 ng TNF 2/21
1 x 104 40 ng IL-1 & TNF 1/21
NSG 40 ng IL-1 & TNF 21/21
B. W eanling 7.5 x 10s diluent 0/12
7.5 x 105 400 ng IL-1 0/11
7.5 x 10s 80 ng IL-1 1/18
7.5 x 104 inactivated IL-1 1/6
7.5 x 104 400 ng IL-1 0/6
7.5 x 10" 80 ng IL-1 0/6
7.5 x 10s 80 ng TN F 0/6
7.5 x 10s 80 ng IL-1 & TNF 1/6
NSG 400 ng IL-1 6/6
NSG 80 ng TNF 6/6
NSG 80 ng IL-1 & TNF 6/6
C. A duit 7.5 x 105 diluent 3/10
7.5 x 105 80 ng IL-1 2/10
7.5 x 105 80 ng TN F 1/11
7.5 x 105 80 ng IL-1 & TNF 1/10
NSG 80 ng IL-1 & TNF 10/10
* Mice were pre-treated with ip 24 hr prior to challenge with murine cytomegalovirus.
** Bglb/c mice one (suckling), three (weanling) and six (adult) weeks old were employed in these experiments.
immunosuppressed hosts, we attempted to 
extend these in vitro  observations to a murine 
CMV system and to compare the effects o f  
cytokines in vitro  and in vivo. The results
Table 3. Effects o f pretreatm ent with interleukin-1 (IL-1) and 
anti-CM V antiserum  on the survival o f weanling mice chal­
lenged with m urine cytomegalovirus.*
Dilution
o f antiserum  used Dose o f IL-1
Survival
#  surviving/ #  challenged
1 :4 0 6/6
1 : 16 0 0/6
1 :4 80 ng 6/6
1 : 16 80 ng 0/6
* Mice were pretreated 24 hr prior to lethal challenge with
7. 5 x 105 pfu o f m urine CM V with either 80 mg o f  IL-1 or a 
com parable am ount o f heat inactivated IL-1, followed 2 hr 
later by 0.2 ml o f a 1 :4  o r 1: 16 dilution of anti-CMV 
hyperim m une antiserum.
reported in this study reveal, that in vitro, 
there are striking decreases in yield of virus 
when the cell monolayer is pretreated with 
IL-1, TNF, or gamma interferon. These 
effects are seen with doses of 1 ng/ml but did 
not increase at higher doses of 10 and 100 ng. 
The decrease in viral titer is approximately 
two logs of virus. This is less than that ob­
served with the other viruses previously stud­
ied, including the closely related herpes 
simplex virus.
Regardless of the in vitro  effects, however, 
there was no benefit o f pretreatment with 
these cytokines individually or in combina­
tion when intact animals were challenged 
with lethal doses o f MCMV. This remained 
true whatever age and degree of immunologic 
maturity of the animal studied. Similarly, the 
administration of these cytokines did not
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produce adverse effects. This was despite the 
ability o f IR -1 to increase ACTH and corti­
costerone in mice. In addition, the adminis­
tration of IL-1 appeared to have no effect on 
the protection provided by hyperimmune 
anti-CMV antiserum. This series o f experi­
ments did not investigate the efficacy in vivo 
of alternate dosing regimens. It is possible 
that repetitive dosing schedules could have a 
protective effect in vivo.
The results reported in this study serve to 
emphasize an important point. The potential 
therapeutic benefits o f cytokine administra­
tion or of an antiviral agent must be assessed 
in the intact animal, not only in cell or tissue 
culture systems. The complexity o f the bio­
logic effects of these agents, and the wide 
range o f cell types that respond to them place 
a premium on their evaluation in intact ani­
mal systems that permit an assessment o f the 
net biologic effect rather than just one aspect 
of their many actions.
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